Hohla Florian, Winder Thomas, Greil Richard, Rick Ferenc G, Block Norman L, Schally Andrew V
Florian Hohla, Richard Greil, III Medical Department with Hematology, Medical Oncology, Hemostasis, Rheumatology and Infectious Diseases, Oncologic Center, Center for Clinical Cancer and Immunology Trials, Laboratory of Immunological and Molecular Cancer Research, Paracelsus Medical University of Salzburg, A-5020 Salzburg, Austria.
World J Gastroenterol. 2014 May 28;20(20):6102-12. doi: 10.3748/wjg.v20.i20.6102.
The introduction of new cytotoxic substances as well as agents that target vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) signaling has improved clinical outcome of patients with metastatic colorectal cancer (mCRC). In this review we summarize the most relevant clinical data on VEGF and EGFR targeting regimens in mCRC. The effects of available treatment strategies for mCRC are often temporary, with resistance and disease progression developing in most patients. Thus, new treatment strategies are urgently needed. Some GI peptides including gastrin and gastrin releasing peptide, certain growth factors such as insulin-like growth factor-I and II and neuropeptides such as growth hormone releasing hormone (GHRH) are implicated in the growth of CRC. Experimental investigations in CRC with antagonistic analogs of bombesin/gastrin-releasing peptide, GHRH, and with cytotoxic peptides that can be targeted to peptide receptors on tumors, are summarized in the second part of the review.
新的细胞毒性物质以及靶向血管内皮生长因子（VEGF）和表皮生长因子受体（EGFR）信号通路的药物的引入，改善了转移性结直肠癌（mCRC）患者的临床结局。在本综述中，我们总结了mCRC中VEGF和EGFR靶向治疗方案的最相关临床数据。mCRC现有治疗策略的效果通常是暂时的，大多数患者会出现耐药和疾病进展。因此，迫切需要新的治疗策略。一些胃肠肽，包括胃泌素和胃泌素释放肽，某些生长因子，如胰岛素样生长因子-I和II，以及神经肽，如生长激素释放激素（GHRH），都与结直肠癌的生长有关。本综述的第二部分总结了用蛙皮素/胃泌素释放肽、GHRH的拮抗类似物以及可靶向肿瘤肽受体的细胞毒性肽对结直肠癌进行的实验研究。
